Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: An in vitro study

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 24-34

  Bernardi, Andressa ^a   Frozza, Rudimar L ^a   Jäger, Eliézer ^a   Figueiró, Fabrício ^a   Bavaresco, Luci ^a   Salbego, Christianne ^a   Pohlmann, Adriana R ^a   Guterres, Sívia S ^a   Battastini, Ana M O ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cell death; Glioma cell; Hippocampal organotypic culture; Indomethacin; Indomethacin ethyl ester; Polymeric nanocapsule

Indexed keywords

DECANOIC ACID DERIVATIVE; INDOMETACIN; INDOMETACIN DERIVATIVE; INDOMETACIN ETHYL ESTER; NANOCAPSULE; OCTANOIC ACID DERIVATIVE; POLYCAPROLACTONE; POLYSORBATE 80; SORBITAN STEARATE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN SLICE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG SELECTIVITY; GLIOMA; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE CULTURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHYSICAL; COLORING AGENTS; CYCLOOXYGENASE 2 INHIBITORS; DRUG COMPOUNDING; GLIOMA; HIPPOCAMPUS; HUMANS; HYDROGEN-ION CONCENTRATION; INDOMETHACIN; MALE; NANOCAPSULES; ORGAN CULTURE TECHNIQUES; PROPIDIUM; RATS; RATS, WISTAR; SUSPENSIONS;

EID: 43549083464     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.026     Document Type: Article

References (53)

1. Aktas Y., Andrieux K., Alonso M.J., Calvo P., Gürsoy R.N., Couvreur P., and Capan Y. Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int. J. Pharm. 298 (2005) 378-383
2. Alonso M.J. Microparticulates systems for the delivery of proteins and vaccines. Drug Pharm. Sci. (1996) 203-242
3. Baek J.S., Wilson C.L., Lee C.H., and Eling E.T. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. Pharm. Exp. Ter. 301 (2002) 1126-1131
4. Beck R.C.R., Pohlmann A.R., Hoffmeister C., Gallas M.R., Collnot E., Schaefer U.F., Guterres S.S., and Lehr C.M. Dexamethasone-loaded nanoparticle-coated microparticles: correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. Eur. J. Pharm. Biopharm. 67 (2007) 18-30
5. Bennis S., Chapey C., Couvreur P., and Robert J. Enhanced cytotoxicity of doxorrubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur. J. Cancer 1 (1994) 89-93
6. Bernardi A., Jacques-Silva M.C., Delgado-Cañedo A., Lenz G., and Battastini A.M.O. Nonsteroidal anti-inflammatory drugs inhibit the growth of C6 and U138-MG glioma cell line. Eur. J. Pharmacol. 532 (2006) 214-222
7. Bernardi A., Bavaresco L., Wink M.R., Jacques-Silva M.C., Delgado-Cañedo A., Lenz G., and Battastini A.M.O. Indomethacin stimulates activity and expression of ecto-5′-nucleotidase/CD73 in glioma cell lines. Eur. J. Pharmacol. 569 (2007) 8-15
8. Bigner S.H., Mark J., Burger P.C., Mahaley M.S., Bullard D.E., Muhlabir L.H., and Bigner D.D. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48 (1988) 405-411
9. Brigger I., Dubernet C., and Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54 (2002) 631-651
10. Brigger I., Morizet J., Aubert G., Chacun H., Terrier-Lacombe M.J., Couvreur P., and Vassal G. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumour targeting. J. Pharmacol. Exp. Ther. 303 (2002) 928-936
11. ® nanospheres-encapsulated doxorrubicin in an orthopic murine brain tumor model. J. Control. Release 100 (2004) 29-40
12. Brioschi A., Zenga F., Zara C.P., Gasco M.R., Ducati A., and Mauro A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?. Neurolog. Res. 29 (2007) 324-330
13. Calvo P., Gouritin B., Chacum H., Desmaele D., D'Angelo J., Noel J.P., Georgin D., Fattal E., Andreux J.P., and Couvreur P. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18 (2001) 1157-1166
14. Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., and Helene C. Adsorption of oligonucleotides onto polysohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11 (1994) 1370-1378
15. Colin de Verdiere A.C., Dubernet C., Nemati F., Soma E., Appel M., and Forte J. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br. J. Cancer 76 (1997) 198-205
16. Couvreur P., Tulkens P., Roland M., Trouet A., and Speiser P. Nanocapsules: a new type of lysosomotropic carrier. Fed. Eur. Biochem. Soc. Lett. 84 (1977) 323-326
17. Cruz L., Soares L.U., Dalla Costa T., Mezzalira G., Silveira N.P., Guterres S.S., and Pohlmann A.R. Diffusion and mathematical modeling of release profiles from nanocarriers. Int. J. Pharm. 313 (2006) 198-205
18. Deen D.F., Chiarodo A., Grimm E.A., Fike J.R., Israel M.A., Kun L.E., Levin V.A., Marton L.J., Packer R.J., and Pegg A.E. Brain Tumor Working Group report on the 9th International Conference on brain Tumor Research and Therapy, Organ System program, National Cancer Institute. J. Neurooncol. vol. 16 (1993)
19. Fessi H., Puisieux F., Devissaguet J.P., Amoury N., and Benita S. Nanocapsules formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 113 (1989) r1-r4
20. Garcia-Garcia E., Andrieux K., Gil S., and Couvreur P. Colloidal carriers and blood-brain (BBB) translocation: a way to deliver drugs to the brain?. Int. J. Pharm. 298 (2005) 274-292
21. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski S.B., Zanella F.E., and Kreuter J. Toxicological studies of doxorrubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol. Lett. 126 (2002) 131-141
22. Greemberg E.R., Baron J.A., Freeman Jr., Mandel J.S., and Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl. Inst. 85 (1993)
23. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., and Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60 (2000) 5599-5602
24. Guterres S.S., Weiss V., de Luca Freitas L., and Pohlmann A.R. Influence of benzyl benzoate as oil core on the physicochemical properties of spray-dried powders from polymeric nanocapsules containing indomethacin. Drug Deliv. 7 (2000) 195-199
25. Holland E.C. Gliomagenesis: genetic alterations and mouse models. Nature 2 (2001) 120-129
26. Holopainen I.E. Organotypic hippocampal slice cultures: a model system to study basic cellular and molecular mechanisms of neuronal cell death, neuroprotection, and synaptic plasticity. Neurochem. Res. 30 (2005) 1521-1528
27. Hu Y.P., Henry-Toulme N., and Robert J. Failure of lipossomal encapsulation of doxorrubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells. Eur. J. Cancer 31A (1995) 389-394
28. Jäger A., Stefani V., Guterres S.S., and Pohlmann A.R. Physico-chemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes. Int. J. Pharm. 338 (2007) 297-305
29. Kalgutkar A.S., Marnett A.B., Crews B.C., and Remmel R.P. Ester and amide derivatives of the nosteroidal anti-inflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J. Med. Chem. 43 (2000) 2860-2870
30. Kim S.Y., and Lee Y.M. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(e-caprolactone) as novel anticancer drug carriers. Biomaterials 22 (2001) 1697-1704
31. Koukourakis M.I., Koukourakis S., Fezoulidis I., Keledis N., Kyras G., Archimandritis S., and Karkavistas N. High tumoral accumulation of stealth lipossomal doxorrubicin (caelyx) in glioblastomas and in metastatic brain tumors. Br. J. Cancer 83 (2000) 1281-1286
32. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20 (2003) 1772-1778
33. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control. Release 99 (2004) 259-269
34. Lamprecht A., and Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 112 (2006) 208-213
35. Lockman P.R., Koziara J., Roder K.E., Paulson J., Abbruscato T.J., Mumper R.J., and Allen D.D. In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm. Res. 20 (2003) 705-713
36. Macklis J.D., and Madison R.D. Progressive incorporation of propidium iodide in cultured mouse neurons correlates with declining electrophysiological status: a fluorescence scale of membrane integrity. J. Neurosci. Methods 31 (1990) 43-46
37. McCarthy J.R., Perez J.M., Brückner C., and Weissleder R. Polymeric nanoparticle preparation that eradicates tumors. Nano Let. 5 (2005) 2552-2556
38. Noraberg J., Kristensen B.W., and Zimmer J. Markers for neuronal degeneration in organotypic slice cultures. Brain Res. Protoc. 3 (1999) 278-290
39. Pohlmann A.R., Soares L.U., Cruz L., Silveira N.P., and Guterres S.S. Alkaline hydrolysis as a tool to determine the association form of indomethacin in nanocapsules prepared with poly(epsilon-caprolactone). Curr. Drug Delivery. 1 (2004) 103-110
40. Poletto F.S., Jäger E., Ré M.I., Guterres S.S., and Pohlmann A.R. Rate-modulating PHBHV/PCL microparticles containing weak acid model drugs. Int. J. Pharm 345 (2007) 70-80
41. Raffin R.P., Colomé L.M., Pohlmann A.R., and Guterres S.S. Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. Eur. J. Pharm. Biopharm. 63 (2006) 198-204
42. Schaffazick S.R., Pohlmann A.R., Dalla-Costa T., and Guterres S.S. Freeze-drying colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur. J. Pharm. Biopharm. 56 (2003) 501-505
43. Schaffazick S.R., Pohlmann A.R., and Guterres S.S. Nanocapsules, nanoemulsion and nanodispersion containing melatonin: preparation, characterization and stability evaluation. Pharmazie 62 (2007) 354-360
44. Seijo B., Fattal E., Treupel L.R., and Couvreus P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and loading. Int. J. Pharm. 62 (1990) 1-7
45. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudziski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70 (2001) 1-20
46. Stoppini L., Buchs P.A., and Muller D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37 (1991) 173-182
47. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15 (2001) 2057-2072
48. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J. Nat. Cancer Inst. 94 (2002) 252-266
49. Valentin L.M., Rodnight R., Geyer A.B., Horn A.P., Tavares A., Cimarosti H., Netto C.A., and Salbego C.G. Changes in heat shock protein 27 phosphorylation and immunocontent in response to preconditioning to oxygen and glucose deprivation in organotypic hippocampal cultures. Neuroscience 118 (2003) 379-386
50. Vinograudov S.V., Bronich T.K., and Kabanov A.V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv. Drug Deliv. Rev. 54 (2002) 135-147
51. Williams C.S., Watson A.J.M., Sheng H., Helou R., Shao J., and DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045-6051
52. Wong H.L., Bendayan R., Rauth A.M., Yongqiang L., and Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Reviews 59 (2007) 491-504
53. Zhang Z., and Feng S. In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules 7 (2006) 1139-1146